

ATENOLOL

Indication	<ul style="list-style-type: none"> Hypertension¹ Arrhythmias²
ORAL	Presentation <ul style="list-style-type: none"> Tablet 50 mg QH-Central Pharmacy product: 2 mg/mL
	Dosage <ul style="list-style-type: none"> 0.5–2 mg/kg once daily <ul style="list-style-type: none"> May be administered in 2 divided doses²
	Preparation (if oral solution unavailable) <ul style="list-style-type: none"> Place 1 tablet (50 mg) into an enteral syringe and mix with 10 mL of water for injection Allow tablet to disperse (this may take several minutes—agitate gently if required) <ul style="list-style-type: none"> Concentration now equal to 5 mg/mL Alternative method (use Noten® or Tensig® brand) <ul style="list-style-type: none"> Crush 1 tablet (50 mg) into a fine powder Disperse in 10 mL of water for injection³ Concentration now equal to 5 mg/mL
	Administration <ul style="list-style-type: none"> Oral/OGT/NGT before feeds
Special considerations	<ul style="list-style-type: none"> Avoid abrupt withdrawal¹ Use with caution if impaired renal function <ul style="list-style-type: none"> Start low dose and up-titrate slowly according to clinical circumstances
Monitoring	<ul style="list-style-type: none"> Intermittent or continuous BP Cardiac
Compatibility	<ul style="list-style-type: none"> Nil known
Incompatibility	<ul style="list-style-type: none"> Nil known
Interactions	<ul style="list-style-type: none"> Calcium channel blockers (e.g. verapamil and diltiazem)^{1,4} Antiarrhythmics (e.g. amiodarone, digoxin)^{1,4} Anaesthetic agents¹, adrenaline (epinephrine)¹ Non-steroidal anti-inflammatory drugs (e.g. ibuprofen and indomethacin)⁵
Stability	<ul style="list-style-type: none"> Tablet <ul style="list-style-type: none"> Store below 25 °C. Protect from light and moisture¹ Oral solution <ul style="list-style-type: none"> Store below 25 °C. Protect from light Use within 1 month of opening Reconstituted solution from tablet <ul style="list-style-type: none"> Use immediately and discard remaining solution
Side effects	<ul style="list-style-type: none"> Hypotension; bradycardia, bronchospasm, dyspnoea, cold extremities; gastrointestinal upset; and wheezing^{1,5}
Actions	<ul style="list-style-type: none"> Cardio selective beta blocker
Abbreviations	BP: blood pressure
Keywords	atenolol, hypertension, arrhythmia



The Queensland Clinical Guideline *Neonatal Medicines* is integral to and should be read in conjunction with this monograph. Refer to the disclaimer. Destroy all printed copies of this monograph after use.

References

1. MIMS Online. Atenolol [Internet]: MIMS Australia; August 2017 [cited 2018 July 2013]. Available from: <https://www.mimsonline.com.au>.
2. British National Formulary for Children (BNFC) online. Atenolol. [Internet]: Royal Pharmaceutical Society; February 2017 [cited 2018 January 09]. Available from: <https://www.medicinescomplete.com>.
3. Burrige N, Deidun D, editors. Australian Don't Rush to Crush Handbook: Therapeutic Options for People Unable to Swallow Solid Oral Medicines: Society of Hospital Pharmacists of Australia; 2011.
4. IBM Micromedex®. Atenolol in IBM Micromedex® (electronic version). Greenwood Village, Colorado, USA. June 2018 [cited 2018 July 13]. Available from: <http://www.micromedexsolutions.com>.
5. Australian Medicines Handbook. Atenolol. [Internet]. Adelaide: Australian Medicines Handbook Pty Ltd; January 2018 [cited 2018 July 13]. Available from: <http://amhonline.amh.net.au>.

Document history

ID number	Effective	Review	Summary of updates
NMed19.001-V1-R24	March 2019	March 2014	Endorsed by Queensland Neonatal Services Advisory Group (QNSAG)